Navigation Links
STALLERGENES: Immunotherapy Tablet Containing Recombinant Allergen (rBet v 1) of Birch Pollen: Positive Results for a Phase IIb/III Trial

ANTONY, France, September 16 /PRNewswire-FirstCall/ -- Stallergenes S.A. has announced the first results of a new phase IIb/III clinical trial (VO59.08) conducted in allergic rhinitis caused by birch pollen and concerning the development of a sublingual immunotherapy tablet containing the recombinant allergen of this pollen, rBet v 1.

This study is the first ever to use a recombinant allergen as an active substance. To Stallergenes' knowledge, the use of a recombinant protein in dry form is also a world first.

The VO59.08 study, conducted during the 2009 pollen season, was a randomized, double-blind, placebo-controlled trial. It included 483 adult patients allergic to birch pollen and suffering from rhinoconjunctivitis symptoms in 30 centers in 8 different countries. The patients were divided into 4 groups: 3 groups treated with sublingual tablets containing 12.5 microg, 25 microg and 50 microg of rBet v 1, respectively, with no dose-titration phase, and one group receiving placebo.

The primary endpoint for analysis of the results was the reduction in average adjusted symptom score (AASS). The 3 treated groups demonstrated a statistically significant reduction in AASS in comparison with placebo (0.002<p<0.03) of approximately 25% over the season as a whole and approximately 30% at its peak. The overall tolerance was very good, notably for the 12.5 microg and 25 microg dosages.

"This study conducted by Stallergenes marks a very important milestone in immunotherapy. It is the first time that clinical development with a regulatory objective has been undertaken with a recombinant allergen. Analysis of all the results should make it possible to select the optimum dose and to define the conditions for the confirmatory phase III study that will be conducted with a view to filing a centralized marketing authorization application with the EMEA.

The rBet v 1 program, launched in 2003 with the signature of a licensing agreement for rBet v 1 produced by Biomay has represented an unprecedented pharmaceutical development effort, together with our manufacturing partner CMC Biologics" says Albert Saporta, Chairman and CEO of Stallergenes.

"We are excited and proud to be part of the rBet v 1 innovative program. As a partner to Stallergenes, CMC is committed to the challenge of producing the world first major recombinant allergens on a large scale" says David Kauffmann, Chairman of CMC Biologics.


Very common in Northern Europe - and especially Germany, the Netherlands, Norway, Sweden and Switzerland, the prevalence of allergic rhinitis caused by birch pollen exceeds 20% in some large cities[1].

The birch pollen season is short - lasting just 1 to 2 months - but intense, and precedes the grass pollen season.


Stalair(R) is the pharmaceutical and clinical development program for immunotherapy being implemented by Stallergenes with a view to obtaining registrations for pharmaceutical products in Europe and, via partnership agreements, with strategic markets outside Europe.

The first tablet resulting from this program, Oralair(R) (grass pollen immunotherapy tablet), is available in Germany for adults and children. This tablet is currently being evaluated in other European countries.

The dust mite immunotherapy tablet, Actair(R) was the subject of a phase IIb/III study in allergic rhinitis in adults during the first half of 2009. A pediatric study has been launched.

Phase IIb/III of the rBet v 1 tablet program has just been completed therefore.

The other allergens concerned by the program are ragweed for the North American market and Japanese cedar pollen for the Japanese market. All together, the program covers 80% of the epidemiology for all markets.


Biomay has more than two decades of expertise in the expression, purification and characterization of recombinant allergens. Biomay offers these allergens off-the-shelf at two quality levels: research-grade and GMP-grade for the production of therapies

Further information about Biomay is available online at:


CMC Biologics is a leading player, in offering integrated services for development and production of biopharmaceutical products. The Company specializes in process development and large-scale manufacturing of pharmaceutical proteins, in compliance with the most stringent cGMP standards, for use in preclinical studies, clinical trials and large-scale commercialization. CMC Biologics offers a broad range of services, including the development of cell lines, development processes, formulations and analytical tests. CMC Biologics has manufacturing sites in Copenhagen, Denmark and Washington, USA.

Further information about CMC Biologics is available online at:


Stallergenes is a European biopharmaceutical company dedicated to immunotherapy treatments for the prevention and treatment of allergy-related respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and asthma. A pioneer and leader in sublingual immunotherapy treatments, Stallergenes devotes 21% of its turnover, in gross terms, to Research and Development and is actively involved in the development of a new therapeutic class: sublingual immunotherapy tablets.

In 2008, Stallergenes had a turnover of 171 million euros and more than 500,000 patients were treated with Stallergenes immunotherapy products.

    Euronext Paris (Compartment B)
    SBF 120.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

    Additional information is available at

[1] Bousquet J. et al. Geographical variation in the prevalence of positive skin prick tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy 2007: 62: 301-309.

SOURCE Stallergenes
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES: 1st Half-Year 2009: Performance Ahead of Expectations
2. STALLERGENES: Strong Sales Growth in 1st Half-Year: up 12% Full-Year Guidance Maintained
3. STALLERGENES: 2008: Strong Performance
4. Stallergenes: 2008: Sales Up 16% - Excellent Performance - Guidance Exceeded
5. Stallergenes: Launch of a Phase III Clinical Trial in Adults for Oralair(R) Grasses in the United States Operating Income Expected to Remain Stable in 2009
6. Stallergenes: Sales at end September 2008: + 17% - 2008 Sales Guidance Revised Upwards: + 14%
7. Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit
8. Stallergenes: Q2 2008 Sales up 18% Revision Upwards of 2008 Sales Growth
9. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
10. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
11. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
Post Your Comments:
(Date:11/24/2015)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be presenting ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. ... will provide a corporate overview. th Annual Oppenheimer ... p.m. ET/10:00 a.m. PT . Jim Mazzola , vice ... overview. --> th Annual Oppenheimer Healthcare Conference in ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential micronutrient ... to proteins, copper is also toxic to cells. With a $1.3 million award ... will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa (P. ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... 2015 Today, LifeBEAM , a ... 2XU, a global leader in technical performance sports ... with advanced bio-sensing technology. The hat will allow ... key biometrics to improve overall training performance. As ... will bring together the most advanced technology, extensive ...
(Date:10/26/2015)... and LAS VEGAS , Oct. ... Labs , an innovator in modern authentication and a ... announced the launch of its latest version of the ... enabling organizations to use standards-based authentication that supports existing ... S3 Authentication Suite is ideal for organizations deploying customer-facing ...
Breaking Biology News(10 mins):